The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance

American Journal of Drug and Alcohol Abuse

Volumn 33, Issue 6, 2007, Pages 769-776

  Stoops, William W ^a   Lile, Joshua A ^a   Lofwall, Michelle R ^a   Rush, Craig R ^a,b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Aripiprazole; Cocaine; Humans; Pharmacotherapy; Physiological effects

Indexed keywords

ARIPIPRAZOLE; COCAINE; NEUROLEPTIC AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PSYCHOLOGICAL ASPECT; RECEPTOR AFFINITY; TEMPERATURE SENSITIVITY;

ADMINISTRATION, INTRANASAL; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; COCAINE; COCAINE-RELATED DISORDERS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; PIPERAZINES; QUESTIONNAIRES; QUINOLONES;

EID: 36248963638     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990701651556     Document Type: Article

References (18)

1. de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M. Pharmacological treatment of cocaine dependence: A systematic review. Addict 2002; 97(8):931-949.
2. Childress AR, O'Brien CP. Dopamine receptor partial agonists could address the duality of cocaine craving. Trends Pharmacol Sci 2000; 21(1):6-9.
3. 2 receptors. J Pharmacol Exp Ther 2002; 302(1):381-389.
4. Stoops WW. Aripiprazole as a potential pharmacotherapy for stimulant dependence: Human laboratory studies with d-amphetamine. Exp Clin Psychopharmacol 2006; 14(4):413-421.
5. Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR. Aripiprazole attenuates the discriminative-stimulus effects of d-amphetamine in humans. Neuropsychopharmacology 2005; 30(11):2103-2114.
6. Stoops WW, Lile JA, Glaser PE, Rush CR. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend 2006; 84(2):206-209.
7. Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW. Caffeine drug discrimination in humans: Acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 1992; 261(3):885-894.
8. Dudish-Poulsen SA, Hatsukami DK. Dissociation between subjective and behavioral responses after cocaine stimuli presentations. Drug Alcohol Depend 1997; 47(1):1-9.
9. Di Marino ME, Haberny KA, Felch LJ, Walsh SL, Preston KL, Bigelow GE. Development of a subject-rated rating scale sensitive to acute cocaine administration. In Problems of Drug Dependence, 1997: Proceedings of the 59th Annual Scientific Meeting. Harris L, ed. Rockville, MD: National Institute on Drug Abuse Research Monograph Series, 1998; 139.
10. Rush CR, Stoops WW, Hays LR, Glaser PEA, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 2003; 306(1):195-204.
11. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676.
12. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100.
13. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39(11):1172-1177.
14. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19.
15. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63(9):763-771.
16. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J Clin Psychopharmacol 2005; 25(4):363-366.
17. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005; 66(6):756-760.
18. Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, Meririnne E. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007; 164(1):160-162.